Ivax Secures Approval for Generic Version of Cancer Drug

Article

WASHINGTON-Ivax Corp. received federal approval for its generic version of the cancer drug Taxol, making possible a less-expensive version of the blockbuster drug. According to the company, distribution of paclitaxel will begin in a matter of weeks. The drug, widely used to treat breast and ovarian cancers, won tentative approval in August. However, because of pending litigation and patent questions, was unable to receive approval. A spokesperson for the company would not comment on the price but stated that generic versions of brand-name drugs typically cost 30% less. Taxol costs about $7,000 for each course of treatment, but the amount varies depending upon the condition. For more information visit www.ivax.com.

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content